Enhancer of zeste homolog 2 expression and its association with clinicopathological characteristics and prognosis in patients with diffuse large B-cell lymphoma
10.3760/cma.j.cn115355-20211009-00461
- VernacularTitle:弥漫大B细胞淋巴瘤zeste基因增强子同源物2表达及其与临床病理特征和预后的关系
- Author:
Hong SU
1
;
Peng BU
;
Jinfen WANG
Author Information
1. 山西省肿瘤医院病理科，太原 030013
- Keywords:
Lymphoma, large B-cell, diffuse;
Enhancer of zeste homolog 2;
Clinicopathological features;
Prognosis
- From:
Cancer Research and Clinic
2022;34(2):102-105
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the expression of enhancer of zeste homolog 2 (EZH2) and its relationship with clinicopathological characteristics and prognosis in patients with diffuse large B-cell lymphoma (DLBCL).Methods:The clinicopathological data of 106 DLBCL patients with detailed follow-up data in Shanxi Provincial Cancer Hospital from January 2009 to December 2018 were retrospectively analyzed, including 30 cases (28%) of germinal center B cell-1ike (GCB) and 76 cases (72%) of non-GCB; and 11 cases of reactive lymph nodes were selected as the control group. EnVision method was used to detect the expressions of EZH2 and c-myc. The correlation of the expressions of EZH2 and c-myc proteins was analyzed, and the association of EZH2 protein with clinicopathological characteristics, overall survival (OS) and progression-free survival (PFS) of patients was also analyzed.Results:The positive expression rates of EZH2 and c-myc proteins were 78.3% (83/106) and 48.1% (51/106), respectively, and neither was expressed in the control group. The positive expression rate of EZH2 protein in non-GCB was higher than that in GCB ( P < 0.01). The expression of EZH2 was correlated with clinical staging, serum lactic dehydrogenase (LDH) level and international prognostic index (IPI) score (all P < 0.01). EZH2 expression was positively correlated with the c-myc protein expression in GCB ( r = 0.74, P < 0.001). Moreover, OS and PFS of EZH2 negative in DLBCL were better than those of EZH2 positive (all P < 0.001). Conclusions:EZH2 overexpression is correlated with advanced clinical staging, increased serum LDH level, high IPI score and non-GCB phenotype. The high expression of EZH2 may be related to the high expression of c-myc, suggesting the poor prognosis of patients with DLBCL.
